Biogen is presenting new data highlighting the potential clinical benefits of Tysabri (natalizumab), Plegridy (peginterferon beta-1a), and Avonex (interferon beta-1a) for the treatment of specific groups of individuals with multiple sclerosis (MS), including pregnant women and patients with relapsing forms of the disease.
The new findings, based on real-world clinical practice data, were presented at the 35th Congress of the European Committee for Treatment and Research in MS (ECTRIMS), held Sept. 11-13 in Stockholm.
“Biogen’s longstanding leadership in MS presents an opportunity to continue evolving the paradigm of care through continued research of some of our most widely prescribed MS therapies, including Tysabri, Plegridy, and Avonex,” Alfred Sandrock Jr., MD, PhD, executive vice president and chief medical officer at Biogen, said in a press release.
“Through thoughtful and rigorous exploration of potential new approaches, like Tysabri extended interval dosing, we are working to optimize patient outcomes,” Sandrock said.
In a poster titled, “Natalizumab is Associated with No Evidence of Disease Activity and with Improvement in Disability and Cognitive Performance in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE 4-Year Results,” researchers present data supporting the real-world long-term effectiveness of Tysabri in patients with early relapsing-remitting MS (RRMS) who do not have antibodies against the John Cunningham (JC) virus — the causative agent of progressive multifocal leukoencephalopathy, a rare brain infection associated with Tysabri treatment.
According to four-year data from the observational, open-label STRIVE trial (NCT01485003), in two to four years of treatment with Tysabri, 70.1% of the patients (110 of 157) achieved a disease-free status, called NEDA (no evidence of disease activity) — defined as no relapses and no confirmed disability progression.
In addition, 83.7% of the patients also achieved MRI NEDA — defined as having no new or enlarged gadolinium-enhancing (GdE) MRI lesions (active lesions), or T2-hyperintense MRI lesions (lesions caused largely by the loss of myelin). In total, 58% achieved overall NEDA, which includes both clinical and MRI NEDA.
Findings also indicated that Tysabri was linked to significant improvements in disability and cognitive performance.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?